These data indicate that many HCPs who manage PV and MF require further education on optimal management strategies for these conditions. As demonstrated by this study, treatment decision support tools can positively influence how HCPs manage patients with PV and MF. - Srdan Verstovsek, MD, PhD
RESTON, Va. (PRWEB) December 13, 2017
Many clinicians suboptimally manage patients with polycythemia vera (PV) and myelofibrosis (MF), according to an analysis of data captured from an online tool developed by Clinical Care Options (CCO) in collaboration with a panel of PV and MF experts. The analysis was presented by Ryan Topping, PhD, at the 59th ASH Annual Meeting & Exposition in Atlanta, Georgia.
Treatment for PV and MF continues to be refined, resulting in educational gaps for many healthcare providers (HCPs) who manage these conditions. In collaboration with a panel of PV and MF experts, CCO developed an online treatment decision support tool to assist HCPs in making optimal management choices for patients with PV and MF. HCPs were asked to enter patient case details into the decision support tool and were surveyed on their intended treatment for the case. They were then provided with management choices for that case from the expert panel.
Comparison of the intended treatment choices of HCPs with expert selections showed that many HCPs would choose suboptimal management strategies for their patients with PV and MF. This was noted for both first-line and second-line therapy for both types of myeloproliferative neoplasms. Of note, after reviewing the tool’s expert management strategy for their patient, 82% of HCPs indicated that they changed the original management plans or had their planned treatment approach confirmed.
According to Srdan Verstovsek, MD, PhD of The University of Texas MD Anderson Cancer Center, who was a member of the tool’s expert panel, “these data indicate that many HCPs who manage PV and MF require further education on optimal management strategies for these conditions. As demonstrated by this study, treatment decision support tools can positively influence how HCPs manage patients with PV and MF.”
“Once again, CCO is proud to be part of this ongoing collaboration and pleased to share the findings of this study with the medical community at large,” said Tina Stacy, PharmD, BCOP, CHCP, Senior Vice President, Educational Strategy and General Manager, Oncology at CCO.
Online treatment decision tools can provide a valuable patient care resource for HCPs. A detailed analysis of this tool was presented at the 59th ASH Annual Meeting & Exposition meeting in Atlanta, Georgia on December 8, 2017. The most recent version of this tool can be found at http://bit.ly/2AFyhMZ
Topping RP, Deininger MW, Mascarenhas J, Mesa RA, Stein BL, Obholz KL, Everly JJ, Verstovsek S. Variance between experts and oncology healthcare providers in managing polycythemia vera and myelofibrosis: analysis of an online treatment decision support tool. Program and abstracts of the 59th annual meeting of the American Society of Hematology; December 9-12, 2017; Atlanta, Georgia. Abstract 2106.
About Clinical Care Options
Clinical Care Options, LLC, is a global leader in the development of innovative educational programs and technology platforms. CCO’s team has been a pioneer in the creation of continuing education and decision support resources for healthcare professionals both in the United States and around the world for more than 2 decades. For more information, visit clinicaloptions.com
Tradd Sanderson | Director of Marketing
Clinical Care Options